dr. martin on sct-related toxicities for patients with mcl
Published 7 years ago • 72 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
1:02
dr. martin on intensive therapy for young patients with mcl
-
1:11
dr. martin on patient preferences with mcl treatment
-
0:43
dr. martin on potential for car t-cell therapy in mcl landscape
-
1:20
dr. martin on the frontline treatment landscape of mcl
-
0:48
dr. martin on the role of transplant in mantle cell lymphoma
-
2:08
dr. peter martin on future treatment approaches in mantle cell lymphoma
-
1:14:44
taking the leap with innovative strategies in mcl
-
33:43
non-hodgkin lymphoma survivor story: mantle cell lymphoma | shari's story, part 2 (treatment)
-
50:04
mantle cell lymphoma: from current treatments to future innovations(podcast)
-
0:57
dr. rule on treatment of young, fit patients with mcl
-
2:34
dr. martin discusses the heterogeneity of mcl
-
1:02
dr. younes on the implications of ibrutinib's approval for patients with mcl
-
1:26
dr. shah discusses autologous transplant in mcl
-
1:28
dr. rule on potential for car t-cell therapy in mcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:21
exploring targeted and car t-cell therapies on the horizon for mcl
-
7:30
treating relapsed/refractory mantle cell lymphoma
-
1:22
dr. rule on searching for a biomarker indicating indolent mcl
-
1:11
dr. goy on lenalidoiode as management for patients with mcl
-
42:29
mantle cell lymphoma (case studies)
-
1:47
challenges in using car-t therapy & btk inhibitors in patients with r/r mcl
-
1:10
dr. hamlin on toxicities associated with ibrutinib and buparlisib in mcl, fl, and dlbcl